Biotech – the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.
 
 
 
 
 
 


Three bubbles that are ready to pop

Cheap money, artificial credit, and zero interest policies have created all sorts of bubbles since the financial crisis of 2008. Dominic Frisby looks at three that are ready to pop.

Chart of the week: The biotech bubble

The Nasdaq Biotechnology index has risen almost sixfold in the past ten year. In the past five, it has quadrupled.

Three of the best biotech stocks to buy now

Biotechnology firms are benefiting from demand from ageing populations. But as Dr Daniel Koller explains, there’s more to the biotech boom than that.

Three biotech stocks to buy as the sector comes of age

Investment manager Carl Harald Janson tips three biotech stocks to profit from the full range of opportunities this exciting sector has to offer.

An exciting future for tech stocks

We live in a golden age of unprecedented technological change. Smart investors should get in early, says Jim Mellon.

Invest for a high-tech future

Technological change is everywhere, says Merryn Somerset Webb. Investors who don’t want to be left behind should read Jim Mellon’s new book.

How Maurice Saatchi is boosting the biotech industry

Biotech companies will soon be able to get new drugs to patients much faster. That’s good news for patients and investors, says Matthew Partridge.

This company could have made a breakthrough in cancer treatment

The best way to improve cancer treatment is early diagnosis. And this small-cap biotech company may have the key to doing just that, says Matthew Partridge.

A revolutionary new cancer treatment – and the blue-chip stock set to benefit

A new kind of cancer therapy could make a big difference to survival rates – and transform the fortunes of one big UK drugs company. Matthew Partridge explains.

How to invest in the battle against ageing

As life expectancy increases, pharmas and biotechs pioneering treatments for the diseases of old age will profit handsomely, says Matthew Partridge.

Showing page 1 of 7